Published in J Control Release on September 18, 2002
The adaptive response of the reticuloendothelial system to major liver resection in humans. Ann Surg (2006) 1.05
Catalytic Properties and Biomedical Applications of Cerium Oxide Nanoparticles. Environ Sci Nano (2015) 0.83
Luminescent proteins for high-speed single-cell and whole-body imaging. Nat Commun (2012) 2.24
piggyBac transposon-mediated long-term gene expression in mice. Mol Ther (2010) 1.33
Visualization and in vivo tracking of the exosomes of murine melanoma B16-BL6 cells in mice after intravenous injection. J Biotechnol (2013) 1.31
Establishment of new preparation method for solid dispersion formulation of tacrolimus. Int J Pharm (2003) 1.26
Time-dependent changes in opsonin amount associated on nanoparticles alter their hepatic uptake characteristics. Int J Pharm (2007) 1.20
Hydrodynamics-based procedure involves transient hyperpermeability in the hepatic cellular membrane: implication of a nonspecific process in efficient intracellular gene delivery. J Gene Med (2004) 1.20
Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J Control Release (2006) 1.15
Novel PEG-matrix metalloproteinase-2 cleavable peptide-lipid containing galactosylated liposomes for hepatocellular carcinoma-selective targeting. J Control Release (2006) 1.15
Macrophage activation by a DNA/cationic liposome complex requires endosomal acidification and TLR9-dependent and -independent pathways. J Leukoc Biol (2004) 1.15
Strategies for in vivo delivery of siRNAs: recent progress. BioDrugs (2010) 1.14
Nonviral approaches for targeted delivery of plasmid DNA and oligonucleotide. J Pharm Sci (2008) 1.13
Nonviral vector-mediated RNA interference: its gene silencing characteristics and important factors to achieve RNAi-based gene therapy. Adv Drug Deliv Rev (2009) 1.12
Targeted delivery systems of small interfering RNA by systemic administration. Drug Metab Pharmacokinet (2007) 1.10
Small interfering RNA delivery to the liver by intravenous administration of galactosylated cationic liposomes in mice. Biomaterials (2006) 1.07
Catalase delivery for inhibiting ROS-mediated tissue injury and tumor metastasis. Adv Drug Deliv Rev (2009) 1.07
Heat shock protein derivatives for delivery of antigens to antigen presenting cells. Int J Pharm (2007) 1.06
Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and simvastatin. Drug Metab Dispos (2002) 1.03
Evaluation of proinflammatory cytokine production induced by linear and branched polyethylenimine/plasmid DNA complexes in mice. J Pharmacol Exp Ther (2006) 1.03
Action mechanism of tachyplesin I and effects of PEGylation. Biochim Biophys Acta (2007) 1.03
Gastrointestinal transit and drug absorption. Biol Pharm Bull (2002) 1.01
Molecular weight-dependent gene transfection activity of unmodified and galactosylated polyethyleneimine on hepatoma cells and mouse liver. Mol Ther (2003) 1.01
Development of novel sustained-release system, disintegration-controlled matrix tablet (DCMT) with solid dispersion granules of nilvadipine (II): in vivo evaluation. J Control Release (2006) 0.99
PEGylated lysine dendrimers for tumor-selective targeting after intravenous injection in tumor-bearing mice. J Control Release (2006) 0.99
Creation of pure nanodrugs and their anticancer properties. Angew Chem Int Ed Engl (2012) 0.99
Skin permeation of propranolol from polymeric film containing terpene enhancers for transdermal use. Int J Pharm (2004) 0.97
Nonviral approaches satisfying various requirements for effective in vivo gene therapy. Biol Pharm Bull (2002) 0.96
Quantitative and temporal analysis of gene silencing in tumor cells induced by small interfering RNA or short hairpin RNA expressed from plasmid vectors. J Pharm Sci (2009) 0.96
PEGylated catalase prevents metastatic tumor growth aggravated by tumor removal. Free Radic Biol Med (2006) 0.96
PEG liposomalization of paclitaxel improved its in vivo disposition and anti-tumor efficacy. Int J Pharm (2011) 0.96
Renal press-mediated transfection method for plasmid DNA and siRNA to the kidney. Biochem Biophys Res Commun (2008) 0.96
Plasmid DNA activates murine macrophages to induce inflammatory cytokines in a CpG motif-independent manner by complex formation with cationic liposomes. Biochem Biophys Res Commun (2002) 0.96
Vector-based in vivo RNA interference: dose- and time-dependent suppression of transgene expression. J Pharmacol Exp Ther (2003) 0.95
Sustained exogenous expression of therapeutic levels of IFN-gamma ameliorates atopic dermatitis in NC/Nga mice via Th1 polarization. J Immunol (2010) 0.95
Efficient targeting to alveolar macrophages by intratracheal administration of mannosylated liposomes in rats. J Control Release (2007) 0.95
Inhibition of experimental hepatic metastasis by targeted delivery of catalase in mice. Clin Exp Metastasis (2004) 0.95
Pre-coating with serum albumin reduces receptor-mediated hepatic disposition of polystyrene nanosphere: implications for rational design of nanoparticles. J Control Release (2004) 0.94
The assembly of a short linear natural cytosine-phosphate-guanine DNA into dendritic structures and its effect on immunostimulatory activity. Biomaterials (2009) 0.94
Inhibition of tumour metastasis by targeted delivery of antioxidant enzymes. Expert Opin Drug Deliv (2006) 0.93
Pharmacokinetic considerations for targeted drug delivery. Adv Drug Deliv Rev (2012) 0.93
Effect of mannose density on mannose receptor-mediated cellular uptake of mannosylated O/W emulsions by macrophages. J Control Release (2006) 0.93
Gene silencing in primary and metastatic tumors by small interfering RNA delivery in mice: quantitative analysis using melanoma cells expressing firefly and sea pansy luciferases. J Control Release (2005) 0.93
Albumin-conjugated PEG liposome enhances tumor distribution of liposomal doxorubicin in rats. Int J Pharm (2007) 0.93
Effect of coupling of albumin onto surface of PEG liposome on its in vivo disposition. Int J Pharm (2006) 0.92
Development of polyethylene glycol-conjugated poly-S-nitrosated serum albumin, a novel S-Nitrosothiol for prolonged delivery of nitric oxide in the blood circulation in vivo. J Pharmacol Exp Ther (2005) 0.92
Human jejunal permeability of cyclosporin A: influence of surfactants on P-glycoprotein efflux in Caco-2 cells. Pharm Res (2003) 0.92
Fetuin mediates hepatic uptake of negatively charged nanoparticles via scavenger receptor. Int J Pharm (2006) 0.91
Prevention of hepatic ischemia/reperfusion injury by prolonged delivery of nitric oxide to the circulating blood in mice. Transplantation (2008) 0.91
Efficient scavenger receptor-mediated uptake and cross-presentation of negatively charged soluble antigens by dendritic cells. Immunology (2004) 0.91
Efficient gene transfection by histidine-modified chitosan through enhancement of endosomal escape. Bioconjug Chem (2010) 0.91
Interaction of polyphenols with proteins: binding of (-)-epigallocatechin gallate to serum albumin, estimated by induced circular dichroism. Chem Pharm Bull (Tokyo) (2009) 0.91
Prevention of pulmonary metastasis from subcutaneous tumors by binary system-based sustained delivery of catalase. J Control Release (2009) 0.91
Gamma-polyglutamic acid-coated vectors for effective and safe gene therapy. J Control Release (2009) 0.91
Reactivation of silenced transgene expression in mouse liver by rapid, large-volume injection of isotonic solution. Hum Gene Ther (2008) 0.90
In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: Involvement of cytotoxic effect on vascular endothelial cells. J Control Release (2008) 0.90
Effect of the content of unmethylated CpG dinucleotides in plasmid DNA on the sustainability of transgene expression. J Gene Med (2009) 0.90
Novel histidine-conjugated galactosylated cationic liposomes for efficient hepatocyte-selective gene transfer in human hepatoma HepG2 cells. J Control Release (2006) 0.90
Enhanced immunostimulatory activity of oligodeoxynucleotides by Y-shape formation. Immunology (2008) 0.89
Inhibition of experimental pulmonary metastasis by controlling biodistribution of catalase in mice. Int J Cancer (2002) 0.89
Determinants for in vivo anti-tumor effects of PEG liposomal doxorubicin: importance of vascular permeability within tumors. Int J Pharm (2008) 0.89
Quantitative analysis of tissue distribution of the B16BL6-derived exosomes using a streptavidin-lactadherin fusion protein and iodine-125-labeled biotin derivative after intravenous injection in mice. J Pharm Sci (2014) 0.89
Enhanced anti-inflammation of inhaled dexamethasone palmitate using mannosylated liposomes in an endotoxin-induced lung inflammation model. Mol Pharmacol (2008) 0.88
Enhanced transfection efficiency into macrophages and dendritic cells by a combination method using mannosylated lipoplexes and bubble liposomes with ultrasound exposure. Hum Gene Ther (2010) 0.88
Effects of inflammatory response on in vivo transgene expression by plasmid DNA in mice. J Pharm Sci (2008) 0.88
Effect of galactose density on asialoglycoprotein receptor-mediated uptake of galactosylated liposomes. J Pharm Sci (2005) 0.88
Intravenous fate of poly(2-(dimethylamino)ethyl methacrylate)-based polyplexes. Eur J Pharm Sci (2003) 0.88
Therapeutic effect of intravenous delivery of lipoplexes containing the interferon-beta gene and poly I: poly C in a murine lung metastasis model. Cancer Gene Ther (2003) 0.88
Mechanistic and empirical modeling of skin permeation of drugs. Adv Drug Deliv Rev (2003) 0.88
Factors affecting drug and gene delivery: effects of interaction with blood components. Crit Rev Ther Drug Carrier Syst (2002) 0.88
Prolongation of residence time of liposome by surface-modification with mixture of hydrophilic polymers. Int J Pharm (2008) 0.88
Biodegradable CpG DNA hydrogels for sustained delivery of doxorubicin and immunostimulatory signals in tumor-bearing mice. Biomaterials (2010) 0.88
Biodistribution characteristics of amino acid dendrimers and their PEGylated derivatives after intravenous administration. J Control Release (2006) 0.88
SOD derivatives prevent metastatic tumor growth aggravated by tumor removal. Clin Exp Metastasis (2008) 0.87
Development of an ultrasound-responsive and mannose-modified gene carrier for DNA vaccine therapy. Biomaterials (2010) 0.87
Prevention of ischemia/reperfusion injury by hepatic targeting of nitric oxide in mice. J Control Release (2009) 0.87
Development of safe and effective nonviral gene therapy by eliminating CpG motifs from plasmid DNA vector. Front Biosci (Schol Ed) (2012) 0.87